one

Phase 2

Recruiting

• Conditions: aortic aneurysm

• Registration Number: JPRN-jRCTs031180361
• Lead Sponsor: Jinzaki Masahiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-18
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. over 20 years old
2. Patients with aortic aneurysm in which diameter is over 45 mm for thoracic aortic aneurysm or 40 mm for abdominal aortic aneurysm
3. Patients with aortic aneurysm which is judeged by ardiovascular surgens not to be necessary for surgery for at least 1 year at the time of informed consent.
4. Patient who agree to participate in this study.

Exclusion Criteria

1. Allergic to FDG and NaF solution
2. History of vasculitis, autoimmune disease, and collagen disease
3. History of Marfan syndrome
4. Hisotyr of chemotherapy and radiation therapy within 8 weeks
5. Definitly or potentially pregnant woman or lactating woman
6. Uncontrolable diabetes mellitus
7. Poor performance status
8. Difficulty in coming to hospital because of poor physical activity
9. History of pshychiatric disorders

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relationship between the uptake of 18F-NaF and 18F-FDG and the enlargement rate of aortic diameter 24 months after PET examinations in the patients with aortic aneurysm.